Regeneron Reports real-world evidence Data for Gilteritinib in Light chain amyloidosis

Regeneron today announced real-world evidence results for Gilteritinib in patients with Light chain amyloidosis. The study demonstrated that Gilteritinib demonstrates durable complete remissions compared to standard of care or placebo. These results provide important insights into the treatment of Light chain amyloidosis and support the continued development of Gilteritinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Gilteritinib was consistent with previous observations, with no new safety signals identified.